🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting over 82 million instances annually. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval signifies a huge turning point in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Worldwide Availability

According to results released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which involves two antibiotics. The research enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have shared optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.